LONDON, Jan 30 (Reuters) - Novo Nordisk will

begin a new late-stage trial of its experimental next-generation

obesity drug CagriSema on Feb. 10, according to a

www.clinicaltrials.gov entry.

The Danish drugmaker last month revealed disappointing

results in a late-stage trial of CagriSema, wiping as much as

$125 billion off its market value. It said then that it would

initiate a new trial in 2025 but did not say when exactly.

The trial is estimated to end in November 2028, the entry

shows. The company did not immediately respond to a request to

comment.

(Reporting by Maggie Fick

Editing by Ros Russell)